Evoke Wealth LLC Purchases New Holdings in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)

Evoke Wealth LLC acquired a new stake in shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) in the 2nd quarter, HoldingsChannel reports. The firm acquired 63,233 shares of the company’s stock, valued at approximately $102,000.

Other hedge funds also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. raised its stake in shares of PMV Pharmaceuticals by 267.2% during the second quarter. Assenagon Asset Management S.A. now owns 260,028 shares of the company’s stock worth $421,000 after purchasing an additional 189,214 shares during the last quarter. Opaleye Management Inc. acquired a new position in PMV Pharmaceuticals in the 1st quarter valued at $802,000. Jacobs Levy Equity Management Inc. raised its position in PMV Pharmaceuticals by 92.4% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 826,704 shares of the company’s stock worth $1,405,000 after buying an additional 397,062 shares during the last quarter. Public Employees Retirement System of Ohio lifted its stake in shares of PMV Pharmaceuticals by 174.2% in the 1st quarter. Public Employees Retirement System of Ohio now owns 22,757 shares of the company’s stock worth $39,000 after acquiring an additional 14,457 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of PMV Pharmaceuticals by 71.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 42,802 shares of the company’s stock valued at $73,000 after acquiring an additional 17,858 shares in the last quarter. 90.20% of the stock is owned by institutional investors and hedge funds.

PMV Pharmaceuticals Stock Down 1.3 %

Shares of PMVP opened at $1.50 on Friday. PMV Pharmaceuticals, Inc. has a 52-week low of $1.18 and a 52-week high of $6.87. The company has a 50-day simple moving average of $1.55 and a 200-day simple moving average of $1.68. The company has a market capitalization of $77.28 million, a PE ratio of -1.13 and a beta of 1.52.

PMV Pharmaceuticals (NASDAQ:PMVP) last issued its earnings results on Thursday, August 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.32. On average, research analysts anticipate that PMV Pharmaceuticals, Inc. will post -1.05 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $5.00 price objective on shares of PMV Pharmaceuticals in a research report on Tuesday, August 20th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $5.75.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.